Biological Activity
ACBI3 is a selective, potent and in vivo active pan-KRAS PROTAC degrader, potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles (DC50=3.9 nM in GP2d cells).
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
References & source
Johannes Popow et al., Targeting cancer with small-molecule pan-KRAS degraders. Science (2024). DOI: 10.1126/science.adm8684 [2] Adrienne D. Cox and Channing J. Der. KRAS takes the road to destruction. Science (2024). DOI: 10.1126/science.ads2150[3] Kim, D., Herdeis, L., Rudolph, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature (2023). https://doi.org/10.1038/s41586-023-06123-3
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.











